Bridge City Capital LLC bought a new position in ADMA Biologics Inc (NASDAQ:ADMA - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 265,689 shares of the biotechnology company's stock, valued at approximately $2,665,000. Bridge City Capital LLC owned approximately 0.12% of ADMA Biologics at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. BlackRock Inc. bought a new stake in ADMA Biologics during the second quarter valued at about $321,037,000. Dimensional Fund Advisors LP raised its position in shares of ADMA Biologics by 3.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 5,005,481 shares of the biotechnology company's stock valued at $45,101,000 after buying an additional 169,843 shares during the period. Bank of America Corp DE boosted its stake in ADMA Biologics by 107.5% during the first quarter. Bank of America Corp DE now owns 3,997,675 shares of the biotechnology company's stock worth $36,019,000 after buying an additional 2,071,338 shares during the period. Nantahala Capital Management LLC acquired a new position in ADMA Biologics during the 2nd quarter worth about $19,753,141. Finally, Ranger Investment Management L.P. purchased a new position in ADMA Biologics in the 2nd quarter valued at approximately $17,706,000. 75.68% of the stock is currently owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
A number of research firms have recently commented on ADMA. Weiss Ratings reiterated a "hold (c)" rating on shares of ADMA Biologics in a research report on Monday, September 14th. Zacks Research upgraded ADMA Biologics from a "strong sell" rating to a "hold" rating in a research report on Wednesday, September 2nd. Finally, Mizuho dropped their price objective on shares of ADMA Biologics from $20.00 to $17.00 and set an "outperform" rating for the company in a research note on Wednesday, July 15th. Three analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, ADMA Biologics currently has an average rating of "Moderate Buy" and a consensus price target of $18.67.
Get Our Latest Report on ADMA Biologics
ADMA Biologics Price Performance
NASDAQ ADMA opened at $11.41 on Monday. ADMA Biologics Inc has a 52 week low of $7.21 and a 52 week high of $20.46. The stock has a market cap of $2.56 billion, a price-to-earnings ratio of 16.30 and a beta of 0.70. The company has a 50-day moving average price of $10.00 and a two-hundred day moving average price of $11.03. The company has a current ratio of 6.97, a quick ratio of 3.81 and a debt-to-equity ratio of 0.49.
ADMA Biologics (NASDAQ:ADMA - Get Free Report) last released its earnings results on Wednesday, August 5th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.16. The firm had revenue of $124.39 million for the quarter, compared to analyst estimates of $125.34 million. ADMA Biologics had a return on equity of 40.17% and a net margin of 32.98%. ADMA Biologics's revenue was up 2.0% compared to the same quarter last year. During the same period in the previous year, the company earned $0.14 earnings per share. Analysts forecast that ADMA Biologics Inc will post 0.78 EPS for the current year.
About ADMA Biologics
(
Free Report)
ADMA Biologics, Inc is a biopharmaceutical company focused on developing, manufacturing and commercializing plasma-derived biologic products for people with compromised or weakened immune systems. The company's activities include collecting human plasma, developing immune globulin therapies and manufacturing products for use in the prevention and treatment of certain infectious diseases.
ADMA's portfolio includes Asceniv, an intravenous immune globulin indicated for primary humoral immunodeficiency disease, and Bivigam, an intravenous immune globulin used for the treatment of primary humoral immunodeficiency.
Read More
Want to see what other hedge funds are holding ADMA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ADMA Biologics Inc (NASDAQ:ADMA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider ADMA Biologics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ADMA Biologics wasn't on the list.
While ADMA Biologics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.